JAK2 and myeloproliferative disorder: Although a specific STAT5 inhibitor has not yet been developed, lestaurtinib (CEP701), a new JAK2 inhibitor that suppresses JAK2/STAT5 signaling is showing promise in clinical trials for myeloproliferative disorders and pancreatic cancer [33].